Headlines about AVEO Pharmaceuticals (NASDAQ:AVEO) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.4610768510314 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

AVEO has been the subject of a number of research reports. BidaskClub raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, June 21st. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, May 4th. Finally, ValuEngine raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $4.05.

Shares of AVEO Pharmaceuticals traded down $0.10, reaching $2.80, on Wednesday, MarketBeat Ratings reports. The company had a trading volume of 2,995,073 shares, compared to its average volume of 1,867,051. The stock has a market capitalization of $336.39 million, a P/E ratio of -17.50 and a beta of 1.51. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of -0.36. AVEO Pharmaceuticals has a one year low of $1.91 and a one year high of $4.24.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.98 million. equities analysts predict that AVEO Pharmaceuticals will post -0.27 EPS for the current fiscal year.

In other news, major shareholder Equity Opportunities Iv Growth acquired 236,479 shares of the stock in a transaction dated Monday, May 21st. The stock was bought at an average price of $2.13 per share, with a total value of $503,700.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ravi Viswanathan acquired 184,179 shares of the stock in a transaction dated Thursday, May 17th. The stock was purchased at an average cost of $2.13 per share, with a total value of $392,301.27. The disclosure for this purchase can be found here. Insiders bought 497,101 shares of company stock valued at $1,058,937 in the last three months. Company insiders own 4.40% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.